

EVIDENCE FOR IMPACT: MEASURING THE IMPACT OF INVESTMENT IN R&D FOR NEGLECTED DISEASES

The Challenge

Since 1999, tens of billions of dollars have been invested in Global Health R&D (GH R&D). G-FINDER shows at nearly \$50 billion since tracking started in 2007. As a result of that unprecedented investment, the ecosystem for GH global health and pandemic preparedness R&D has generated hundreds of new products in the pipeline, with several moving to the delivery stage. At the same time, there is no established and credible process to evaluate the global health pipeline, to assess past investments and to inform investment decisions, tradeoffs or required shifts in the product development (PD) ecosystem moving forward.

Purpose

Through active engagement with donors and other key stakeholders, this project seeks to establish a framework that the community can leverage to assess the health and economic impact of the past 20 years of investment in R&D for neglected diseases and emerging infectious diseases.

Deliverables

- An assessment of the options available for evaluating the success/impact of global health R&D investments, including the anticipated level of effort required to collect particular pieces of data or conduct certain analyses.
- An estimation of each type of data/analysis and the level of confidence a funder might have in making certain assertions on their return on global health R&D investments.
- A comprehensive overview of products approved for neglected and emerging infectious diseases since 1999, including key attributes and organizations involved in their development
- A mapping of the available evidence for each approved product against agreed indicators for research and health program outputs, and policy, health and economic outcomes
- An up-to-date database of the current R&D pipeline for neglected and emerging infectious diseases, including key attributes and organizations involved in development, mapped against consensus R&D priorities (and TPPs/PPCs where applicable)
- A report demonstrating the impact of the last two decades of investment in global health R&D, based on the collated evidence and global funding data
- A validated framework and methodology that could be used for demonstrating the return on investment in global health R&D – including in areas not covered by this project – and for ongoing monitoring of the health of the R&D ecosystem

Impact

The project will showcase the impact of the last two decades of investment in global health R&D, as well as provide a validated framework and methodology for demonstrating the return on investment in global health R&D, which can also be used beyond neglected and emerging infectious diseases.

As such, the project will build the foundation and tools for continuous evaluation allowing stakeholders across the entire global health R&D eco-system to better strategize and plan for their investments, as well as course correct towards achieving greater impact to improve the health of individuals and populations.

Engagement

As the project lead, Policy Cures Research, will bring to bear our own expertise in global health R&D investment and pipeline tracking, as well as convene a core consortium of cross-disciplinary partners, which will be responsible for methodology design, evidence collection, mapping, analysis and production of key outputs.

The project team and the consortium of partners will count on engagement from the Expert Advisory Group. The Expert Advisory Group will provide technical guidance, expertise and blind spot navigation to the process led by the PCR multi-partner team. It will include three groups focusing on: funding and investment, health and economic impact, and advocacy and dissemination.

Contact us

Andrew Tuttle, Director of Research, atuttle@polycuresresearch.org

Vanessa Candeias, Senior Analyst, vcandeias@polycuresresearch.org

Nick Chapman, CEO, nchapman@polycuresresearch.org

Anna Doubell, COO, adoubell@polycuresresearch.org